Indian Journal of PsychiatryIndian Journal of Psychiatry
Home | About us | Current Issue | Archives | Ahead of Print | Submission | Instructions | Subscribe | Advertise | Contact | Login 
    Users online: 849 Small font sizeDefault font sizeIncrease font size Print this article Email this article Bookmark this page
Search Again
 Back
 Table of Contents
 
 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Article Access Statistics
 Reader Comments
 Email Alert
 Add to My List
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed442    
    Printed27    
    Emailed0    
    PDF Downloaded41    
    Comments [Add]    

Recommend this journal

 
ARTICLE
Year : 1998  |  Volume : 40  |  Issue : 3  |  Page : 247-253

Risperidone in Indian Patients with Schizophrenia


1 Professor & Head, Department of Psychiatry, King George's Medical College, Lucknow, India
2 Director, Institute of Mental Health, Chennai, India
3 Director National Institute of Mental Health & Neuro Sciences, Bangalore, India
4 Professor & Head, Department of Psychiatry, BYL Nair Charitable Hospital, Mumbai, India
5 Professor, Department of Psychiatry, Deccan College of Medical Sciences, Hyderabad, India
6 Additional Professor, National Institute of Mental Health & Neuro Sciences, Bangalore, India
7 Hon. Professor, Department of Psychiatry. Seth GS Medical College, & KEM Hospital, Mumbai, India
8 Associate Professor, Department of Psychiatry, King George's Medical College, Lucknow, India
9 Assistant Professor of Psychiatry, Institute of Mental Health, Chennai, India
10 Clinical Research Scientist, Ranbaxy Laboratories Ltd., Gurgaon, India
11 Clinical Research Physician, Ranbaxy Laboratories Ltd., Gurgaon, India
12 Head-Clinical Research, Ranbaxy Laboratories Ltd., Gurgaon, India
13 Assistant Director, Medical Affairs & Clinical Research, Ranbaxy Laboratories Ltd., Gurgaon, India
14 Vice President, Medical Affairs & Clinical Research, Ranbaxy Laboratories Ltd., Gurgaon, India

Correspondence Address:
A K Agarwal
Professor & Head, Department of Psychiatry, King George's Medical College, Lucknow
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 21494480

Rights and PermissionsRights and Permissions

Conventional antipsychotic agents are not effective against negative symptoms of schizophrenia and are also noted for their extrapyramidal side effects. Risperidone is a noval antipsychotic agent whose dual antagonism of dopamine and serotonin receptors is believed to underlie its efficacy against negative symptoms and the low incidence of extrapyramidal side effects. An open, non-comparative study of seven weeks duration was performed to evaluate risperidone in the treatment of schizophrenia in Indian patients. Previous antipsychotic therapy was discontinued for a week before risperidone therapy was initiated. At the end of six weeks of risperidone therapy, clinical improvement (≥ 20% reduction in total score on positive and negative syndrome scale for schizophrenia (PANSS;; was shown by 128 (87.7%) of the 146 evaluable patients. Statistically significant reduction (p <0.05) occurred in the total score of this scale and in the subscale scores for positive, negative and general psychopathology symptoms and in the clinical global impression severity score. The number of patients with adverse experiences were 108 (65.5%) at baseline and 120 (72.7%) at the end of risperidone therapy. Extrapyramidal symptoms, seen in 65 (39.4%) patients compared to 22 (13.3%) patients at baseline, were largely mild to moderate in intensity.



[PDF]*

        

Print this article         Email this article